Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ)

CAPS Rating: 3 out of 5

A specialty pharmaceutical company, which focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.

Results 1 - 20 of 39 : 1 2 Next »

Recs

0
Member Avatar murphydevani (72.57) Submitted: 8/21/2015 8:49:42 AM : Underperform Start Price: $180.50 JAZZ Score: +19.31

Target $176 - $170 - $162

Recs

0
Member Avatar PuddinHead42 (34.60) Submitted: 11/2/2014 7:11:30 PM : Outperform Start Price: $169.15 JAZZ Score: -13.69

Great growth fundies on this stock and reporting this week so taking a CAPS chance on it. If it breaks out past its pivot point on volume I will buy it with real money. IBD composite rating of 99.

DEVELOPS SPECIALTY DRUGS IN THE THERAPEUTIC AREAS OF NARCOLEPSY, ONCOLOGY, PAIN, PSYCHIATRY AND OTHERS.

Recs

0
Member Avatar supplyside2 (< 20) Submitted: 8/4/2014 12:48:39 PM : Outperform Start Price: $136.75 JAZZ Score: +2.40

Great sales 2nd qtr

Recs

0
Member Avatar DugdaleTiki (47.02) Submitted: 3/3/2014 9:25:10 AM : Outperform Start Price: $147.28 JAZZ Score: -10.12

2014 Sabrient Pick

Recs

0
Member Avatar 1picks (86.19) Submitted: 1/13/2014 2:24:18 PM : Outperform Start Price: $147.27 JAZZ Score: -11.50

Sabrient

Recs

0
Member Avatar exoblight (< 20) Submitted: 1/4/2014 12:39:20 PM : Outperform Start Price: $127.00 JAZZ Score: +5.25

Gentium acquisition likely to improve bottom line

Recs

0
Member Avatar SqwiiTrader (< 20) Submitted: 12/13/2013 3:53:00 AM : Underperform Start Price: $115.91 JAZZ Score: -13.33

bearish engulfing

Recs

1
Member Avatar grankh (71.20) Submitted: 10/21/2013 1:08:23 AM : Outperform Start Price: $82.98 JAZZ Score: +59.43

Another stock I own personally.

Sales have grown 80% per year on average since 2010. EPS has grown 56% over the past 18 months. The profit margin has fluctuated considerably, so not joy there. The earned-on-equity has fallen in each of the past 2 years, so the wrong trend. Debt has fluctuated also, though is generally down over the past 3 years. The P/E is above its recent average, but lower than it reached in 2010 and 2011, so not unreasonable, (though its earned-on-equity was much higher in those years, so the higher P/E was justified). The PEG ratio is attractive. The company does NOT pay a dividend, so sadness in that area. I mainly bought this stock due to the rapid growth in Sales and EPS, so see if the stock can continue its rapid, upward trajectory.

Even assuming a growth rate at less than half what the company has been growing at over the past few years, I think this stock could gain 16% or more annually for the next 5 years. However, if its earned-on-equity keeps falling, I may revisit this holding to see if I think it can still grow for me at the rate I want it to, especially since it will not pay me a dividend to offset any potential downside due to the lower earnings growth rate. So one to keep an eye on, and hope the growth rates are maintained for a while longer.

Recs

0
Member Avatar talkingdog (81.43) Submitted: 9/26/2013 7:55:22 AM : Outperform Start Price: $88.39 JAZZ Score: +47.02

underpriced?

Recs

0
Member Avatar awallejr (60.34) Submitted: 9/11/2013 8:15:09 PM : Outperform Start Price: $86.01 JAZZ Score: +51.68

Heard about this stock on Pimm Fox's radio show. Kind of wish I heard about it a year ago. Despite its run up it still looks cheap.

Recs

0
Member Avatar chris293 (48.52) Submitted: 9/11/2013 8:12:17 PM : Outperform Start Price: $86.01 JAZZ Score: +51.68

This sounds like the drug company of choice for people with any number of problems.

Recs

0
Member Avatar onecandream (65.85) Submitted: 9/2/2013 11:07:20 AM : Outperform Start Price: $88.95 JAZZ Score: +42.96

IBD 50

Recs

0
Member Avatar manirg (< 20) Submitted: 7/30/2013 6:20:40 PM : Outperform Start Price: $75.03 JAZZ Score: +76.68

very undervalued

Recs

0
Member Avatar Pops61 (24.03) Submitted: 3/12/2013 1:41:20 AM : Outperform Start Price: $59.91 JAZZ Score: +116.52

Several drugs for mental illness and non-opiod pain management. Sold under performing subsidiary in June 2012. Fwd P/E 9.26. Upgrade with Target price 87.10.

Recs

0
Member Avatar callumturcan (91.76) Submitted: 2/26/2013 2:36:34 PM : Outperform Start Price: $56.64 JAZZ Score: +125.59

Lots of growth at a cheap valuation

Recs

0
Member Avatar HIGHG33K (80.36) Submitted: 7/9/2012 3:33:53 PM : Outperform Start Price: $45.37 JAZZ Score: +175.77

With hot biotech sector and decent value.

Recs

0
Member Avatar valueable (42.47) Submitted: 6/24/2012 7:37:14 PM : Outperform Start Price: $48.57 JAZZ Score: +160.38

Jazz Pharmaceuticals is a great business with a great balance sheet. If a company can pay off all its debt (Jazz doesn't have any debt) and its total liability with just the cash it has on hand i don't know about you but to me that company has great balance sheet.

Recs

0
Member Avatar rustam5 (64.12) Submitted: 4/11/2012 1:03:58 PM : Outperform Start Price: $47.17 JAZZ Score: +165.61

DRUGS

Recs

0
Member Avatar augeryv (< 20) Submitted: 2/24/2012 8:47:59 PM : Outperform Start Price: $51.30 JAZZ Score: +138.91

3 orpheans drugs can boost their income.This pharmcateutique can be a medium size pharma in thenext 2-4 years with market value arround $10b

Recs

0
Member Avatar srettun (< 20) Submitted: 1/23/2012 9:53:51 PM : Outperform Start Price: $47.00 JAZZ Score: +159.39

breaking out of cup and handle base

Results 1 - 20 of 39 : 1 2 Next »

Featured Broker Partners